Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: Comparison with L-DOPA therapy

Molecular Brain Research

Volumn 49, Issue 1-2, 1997, Pages 55-62

  Morissette, Marc ^a,b   Goulet, Martin ^a,b   Soghomonian, Jean Jacques ^a,b   Blanchet, Pierre J ^a,b   Calon, Frédéric ^a,b   Bédard, Paul J ^a,b   Di Paolo, Thérèse ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Caudate putamen; Dopamine agonist; Hybridization, in situ; L DOPA; MPTP monkey; Parkinson; Preproenkephalin

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; LEVODOPA; MESSENGER RNA; PREPROENKEPHALIN; U 91356A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; CAUDATE NUCLEUS; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG TOLERANCE; DYSKINESIA; FEMALE; GENE EXPRESSION REGULATION; HISTOCHEMISTRY; IN SITU HYBRIDIZATION; LONG TERM CARE; MONKEY; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSONISM; PRIORITY JOURNAL; PUTAMEN; SUBCUTANEOUS DRUG ADMINISTRATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AMINOQUINOLINES; ANIMALS; CAUDATE NUCLEUS; DOPAMINE AGONISTS; ENKEPHALINS; FEMALE; IMIDAZOLES; IN SITU HYBRIDIZATION; LEVODOPA; MACACA FASCICULARIS; OVARIECTOMY; PARKINSON DISEASE, SECONDARY; PROTEIN PRECURSORS; PUTAMEN; RECEPTORS, DOPAMINE D2; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

ANIMALIA; MACACA FASCICULARIS; PARKINSONIA;

EID: 0030722477     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(97)00123-X     Document Type: Article

References (54)

1. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12:1989;366-375.
2. Allen J.M., Cross A.J., Teats J.C., Ghatei M.A., McGregor G.P., Close S.P., Pay S., Marriott A.S. Neuropeptides and dopamine in the marmoset. Effect of treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): an animal model for Parkinson's disease? Brain. 109:1986;143-157.
3. Asselin M.-C., Soghomonian J.J., Côté P.-Y., Parent A. Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys. NeuroReport. 5:1994;2137-2140.
4. Augood S.J., Emson P.C., Mitchell I.J., Boyce S., Clarke C.E., Crossman A.R. Cellular localisation of enkephalin gene expression in MPTP-treated cynomolgus monkeys. Mol. Brain. Res. 6:1989;85-92.
5. Beckstead R.M. N-Methyl-D-aspartate acutely increases proenkephalin mRNA in the rat striatum. Synapse. 21:1995;342-347.
6. 2 agonist (U-91356A) in MPTP-exposed monkeys. J. Pharmacol. Exp. Ther. 272:1995;854-859.
7. A receptors in the striatopallidal complex. Brain Res. 680:1995;43-52.
8. Campbell K., Bjorklund A. Prefrontal cortico-striatal afferents maintain increased enkephalin gene expression in the dopamine-denervated rat striatum. Eur. J. Neurosci. 6:1994;1371-1383.
9. Chesselet M.F., Delfs J.M. Basal ganglia and movement disorders - an update. Trends Neurosci. 19:1996;417-422.
10. Comb M., Seeburg P.H., Adelman J., Eiden L., Herberd E. Primary structure of the human Met- and Leu-enkephalin precursor and its mRNA. Nature. 295:1982;663-666.
11. Crossman A.R. Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders. Neuroscience. 23(1):1987;1-40.
12. Crossman A.R. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Movement Dis. 5:1990;100-108.
13. Dacko S., Schneider J.S. Met-enkephalin immunoreactivity in the basal ganglia in symptomatic and asymptomatic MPTP-exposed monkeys: correlation with degree of parkinsonian symptoms. Neurosci. Lett. 127:1991;49-52.
14. DeVries T.J., Jonker A.J., Voorn P., Mulder A.H., Schoffelmeer A.N.M. Adaptive changes in rat striatal preproenkephalin expression and dopamine-opioid interactions upon chronic haloperidol treatment during different development stages. Dev. Brain Res. 78:1994;175-181.
15. 2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias. Synapse. 18:1994;178-189.
16. 2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin. Brain Res. 581:1992;261-268.
17. Engber T.M., Susel Z., Kuo S., Gerfen C.R., Chase T.N. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res. 552:1991;113-118.
18. Filion M., Tremblay L., Bédard P.J. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res. 547:1991;142-151.
19. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 250:1990;1429-1432.
20. Gerfen C.R., McGinty J.F., Young W.S. III Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. J. Neurosci. 11:1991;1016-1031.
21. Gerfen C.R., Young W.S. III Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study. Brain Res. 460:1988;161-167.
22. Goto S., Hirano A., Matsumoto S. Met-enkephalin immunoreactivity in the basal ganglia in Parkinson's disease and striatonigral degeneration. Neurology. 40:1990;1051-1056.
23. Grafe M.R., Forno L.S., Eng L.F. Immunocytochemical studies of substance P and Met-enkephalin in the basal ganglia and substantia nigra in Huntington's, Parkinson's and Alzheimer's diseases. J. Neuropathol. Exp. Neurol. 44:1985;47-59.
24. Hajji M.D., Salin P., Kerkerian-Le Goff L. Chronic dizocilpine maleate (MK-801) treatment suppresses the effects of nigrostriatal dopamine deafferentation on enkephalin but not on substance P expression in the rat striatum. Eur. J. Neurosci. 8:1996;917-926.
25. Herrero M.T., Augood S.J., Hirsch E.C., Javoy-Agid F., Luquin M.R., Agid Y., Obeso J.A., Emson P.C. Effects of L-DOPA on prepoenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience. 68:1995;1189-1198.
26. Jaber M., Normand E., Bloch B. Effect of reserpine treatment on enkephalin mRNA level in the rat striatum: an in situ hybridization study. Mol. Brain Res. 32:1995;156-160.
27. Jaber M., Tison F., Fournier M.C., Bloch B. Differential influence of haloperidol and sulpiride on dopamine receptors and peptide mRNA levels in the rat striatum and pituitary. Mol. Brain Res. 23:1994;14-20.
28. Jiang H.-K., McGinty J.F., Hong J.S. Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes. Brain Res. 507:1990;57-64.
29. Jolkkonen J., Jenner P., Marsden C.D. L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. Mol. Brain Res. 32:1995;297-307.
30. 2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J. Comp. Neurol. 355:1995;418-426.
31. Le Moine C., Normand E., Guitteny A.F., Fouque B., Teoule R., Bloch B. Dopamine receptor gene expression by enkephalin neurons in rat forebrain. Proc. Natl. Acad. Sci. USA. 87:1990;230-234.
32. Lu W., Harber S.N. In situ hybridization histochemistry: a new method for processing material stored for several years. Brain Res. 578:1992;155-160.
33. Mauborgne A., Javoy-Agid F., Legrand J.C., Agid Y., Cesselin F. Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains. Brain Res. 268:1983;167-170.
34. 1 dopamine receptor antagonist. Neurosci. Lett. 125:1991;201-204.
35. Nisenbaum L.K., Kitai S.T., Gerfen C.R. Dopaminergic and muscarinic regulation of striatal enkephalin and substance P messenger RNAs following striatal dopamine denervation: effects of systemic and central administration of quinpirole and scopolamine. Neuroscience. 63:1994;435-449.
36. Oertel W.H., Mugnaini E. Immunocytochemical studies of GABAergic neurons in rat basal ganglia and their relations to other neuronal systems. Neurosci. Lett. 47:1984;233-238.
37. Parent A., Hazrati L.-N. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop Brain Res. 20:1995;91-127.
38. Parent A., Hazrati L.-N. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry Brain Res. Rev. 20:1995;128-154.
39. Parent A., Lavoie B. The heterogeneity of the mesostriatal dopaminergic system as revealed in normal and parkinsonian monkeys. Adv. Neurol. 60:1993;25-33.
40. Pérez-Otaño O., Herrero M.T., Luquin M.R., Obeso J.A., Del Rio J. Chronic MPTP treatment reduces substance P and Met-enkephalin content in the basal ganglia of the marmoset. Brain Res. 585:1992;156-160.
41. Ribak C.E., Vaughn J.E., Roberts E. The GABA neurons and their axon terminals in the rat corpus striatum as demonstrated by GAD immunocytochemistry. J. Comp. Neurol. 187:1979;261-284.
42. 2 receptor mRNAs in the adult rat striatum. Brain Res. 621:1993;249-259.
43. Szabo J., Cowan W.M. A stereotaxic atlas of the brain of the cynomolgus monkey (Macaca fascicularis). J. Comp. Neurol. 222:1984;265-300.
44. 5-enkephalin in the human brain. Brain Res. 280:1983;379-382.
45. Taquet H., Nomoto M., Rose S., Jenner P., Javoy-Agid F., Mauborgne A., Benoliel J.J., Legrand J.C., Agid Y. Levels of Met-enkephalin, Leu-enkephalin, substance P and cholecystokinin in the brain of the common marmoset following long term 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine treatment. Neuropeptides. 12:1988;105-110.
46. Taylor M.D., De Ceballos M.L., Rose S., Chong P.N., Jenner P., Marsden C.D. Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP. J. Neural Transm. - Parkinson's Dis. Dement. Sect. 3:1991;99-108.
47. Taylor M.D., De Ceballos M.L., Rose S., Jenner P., Marsden C.D. Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia. Eur. J. Pharmacol. 219:1992;183-192.
48. Tenovuo O., Rinne U.K., Viljanen M.K. Substance P immunoreactivity in the post-mortem parkinsonian brain. Brain Res. 303:1984;113-116.
49. Uhl G.R., Navia B., Douglas J. Differential expression of preproenkephalin and preprodynorphin mRNAs in striatal neurons: high levels of preproenkephalin expression depend on cerebral cortical afferents. J. Neurosci. 8:1988;4755-4764.
50. Voorn P., Roest G., Groenewegen H.J. Increase of enkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesions. Brain Res. 412:1987;391-396.
51. 2 receptor regulation of preproenkephalin and preprodynorphin mRNA in rat striatum following acute injection of amphetamine or methamphetamine. Synapse. 22:1996;114-122.
52. Young W.S. III, Bonner T.I., Brann M.R. Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc. Natl. Acad. Sci. USA. 83:1986;9827-9831.
53. Zamir N., Skofitsch G., Bannon M.J., Helke C.J., Kopin I.J., Jacobowitz D.M. Primate model of Parkinson's disease: alterations in multiple opioid systems in the basal ganglia. Brain Res. 322:1984;356-360.
54. Zeng B.-Y., Jolkkonen J., Jenner P., Marsden C.D. Chronic L-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat. Neuroscience. 66:1995;19-28.